chloromethyl (3-(nitrooxy)propyl) carbonate | 1314004-72-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: chloromethyl (3-(nitrooxy)propyl) carbonate
• 英文别名: chloromethyl 3-nitrooxypropyl carbonate
• CAS: 1314004-72-2
• 化学式: C₅H₈ClNO₆
• 分子量: 213.575
• InChiKey: GMCFKCXZSSXOLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  chloromethyl (3-(nitrooxy)propyl) carbonate 、 阿司匹林 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.25h， 以75%的产率得到((3-nitrooxypropyloxy)carbonyl)oxymethyl 2-(acetyloxy)-benzoate
  参考文献：
  名称：

  New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins

  摘要：

  A new series of (((R-oxy)carbonyl)oxy)methyl esters of aspirin (ASA), bearing nitric oxide (NO) or hydrogen sulfide (H2S) releasing groups, was synthesized, and the compounds were evaluated as new ASA co-drugs. All the products were quite stable in buffered solution at pH 1 and 7.4. Conversely, they were all rapidly metabolized, producing ASA and the NO/H2S releasing moiety used for their preparation. Consequent on ASA release, the compounds were capable of inhibiting collagen-induced platelet aggregation of human platelet-rich plasma (PRP). The simple NO/H2S donor substructures were able to relax contracted rat aorta strips, with a NO- and H2S-dependent mechanism, respectively, but they either did not trigger antiaggregatory activity or displayed antiplatelet potency markedly below that of the related co-drug. The new products might provide a safer and improved alternative to the use of ASA principally in its anti-inflammatory and antithrombotic applications.

  DOI：

  10.1021/jm2004514
• 作为产物：
  描述：

  3-(nitrooxy)propan-1-ol 、 氯甲酸氯甲酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以83%的产率得到chloromethyl (3-(nitrooxy)propyl) carbonate
  参考文献：
  名称：

  New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins

  摘要：

  A new series of (((R-oxy)carbonyl)oxy)methyl esters of aspirin (ASA), bearing nitric oxide (NO) or hydrogen sulfide (H2S) releasing groups, was synthesized, and the compounds were evaluated as new ASA co-drugs. All the products were quite stable in buffered solution at pH 1 and 7.4. Conversely, they were all rapidly metabolized, producing ASA and the NO/H2S releasing moiety used for their preparation. Consequent on ASA release, the compounds were capable of inhibiting collagen-induced platelet aggregation of human platelet-rich plasma (PRP). The simple NO/H2S donor substructures were able to relax contracted rat aorta strips, with a NO- and H2S-dependent mechanism, respectively, but they either did not trigger antiaggregatory activity or displayed antiplatelet potency markedly below that of the related co-drug. The new products might provide a safer and improved alternative to the use of ASA principally in its anti-inflammatory and antithrombotic applications.

  DOI：

  10.1021/jm2004514

文献信息

• NO-RELEASING NITROOXY-CHROMENE CONJUGATES
  申请人：Euclises Pharmaceuticals, Inc.

  公开号：EP3094333B1

  公开（公告）日：2020-10-14
• New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins
  作者：Loretta Lazzarato、Konstantin Chegaev、Elisabetta Marini、Barbara Rolando、Emily Borretto、Stefano Guglielmo、Sony Joseph、Antonella Di Stilo、Roberta Fruttero、Alberto Gasco

  DOI：10.1021/jm2004514

  日期：2011.8.11

  A new series of (((R-oxy)carbonyl)oxy)methyl esters of aspirin (ASA), bearing nitric oxide (NO) or hydrogen sulfide (H2S) releasing groups, was synthesized, and the compounds were evaluated as new ASA co-drugs. All the products were quite stable in buffered solution at pH 1 and 7.4. Conversely, they were all rapidly metabolized, producing ASA and the NO/H2S releasing moiety used for their preparation. Consequent on ASA release, the compounds were capable of inhibiting collagen-induced platelet aggregation of human platelet-rich plasma (PRP). The simple NO/H2S donor substructures were able to relax contracted rat aorta strips, with a NO- and H2S-dependent mechanism, respectively, but they either did not trigger antiaggregatory activity or displayed antiplatelet potency markedly below that of the related co-drug. The new products might provide a safer and improved alternative to the use of ASA principally in its anti-inflammatory and antithrombotic applications.